Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
Jackson DJ, Pelaia G, Emmanuel B, Tran TN, Cohen D, Shih VH, Shavit A, Arbetter D, Katial R, Rabe APJ, Garcia Gil E, Pardal M, Nuevo J, Watt M, Boarino S, Kayaniyil S, Chaves Loureiro C, Padilla-Galo A, Nair P.
Jackson DJ, et al. Among authors: tran tn.
Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023. Online ahead of print.
Eur Respir J. 2024.
PMID: 38575162